The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Low-Grade Gliomas
Open accessAbstract
Low-grade gliomas (LGGs) are a diverse group of primary brain tumors that often arise in young, otherwise healthy patients and generally have an indolent course with longer-term survival in comparison with high-grade gliomas. Treatment options include observation, surgery, radiation, chemotherapy, or a combined approach, and management is individualized based on tumor location, histology, molecular profile, and patient characteristics. Moreover, in this type of brain tumor with a relatively good prognosis and prolonged survival, the potential benefits of treatment must be carefully weighed against potential treatment-related risks. We review in this article current management strategies for LGG, including surgery, radiotherapy, and chemotherapy. In addition, the importance of profiling the genetic and molecular properties of LGGs in the development of targeted anticancer therapies is also reviewed. Finally, given the prevalence of these tumors in otherwise healthy young patients, the impact of treatment on neurocognitive function and quality of life is also evaluated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Response criteria for phase II studies of supratentorial malignant glioma.
Macdonald, D. R., Cascino, T. L., Schold, S. C., & Cairncross, J. G. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.7.1277 · Cited by 2,409
Karim, A. B. M. F., Maat, B., Hatlevoll, R., Menten, J., Rutten, E. H. J. M., Thomas, D. G. T., Mascarenhas, F., Horiot, J. C., Parvinen, L. M., van Reijn, M., et al. (1996) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(96)00352-5 · Cited by 694
Jakola, A. S., Myrmel, K. S., Kloster, R., Torp, S. H., Lindal, S., Unsgård, G., & Solheim, O. (2012) · JAMA · doi:10.1001/jama.2012.12807 · Cited by 641
Andronesi, O. C., Kim, G. S., Gerstner, E., Batchelor, T., Tzika, A. A., Fantin, V. R., Vander Heiden, M. G., & Sorensen, A. G. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3002693 · Cited by 438
Self-citation
Cited by
CGCG clinical practice guidelines for the management of adult diffuse gliomas
Jiang, T., Mao, Y., Ma, W., Mao, Q., You, Y., Yang, X., Jiang, C., Kang, C., Li, X., Chen, L., et al. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.01.024 · Cited by 607
Boron neutron capture therapy: Current status and future perspectives
Dymova, M. A., Taskaev, S. Y., Richter, V. A., & Kuligina, E. V. (2020) · Cancer Communications · doi:10.1002/cac2.12089 · Cited by 339
Ferraris, C., Cavalli, R., Panciani, P. P., & Battaglia, L. (2020) · International Journal of Nanomedicine · doi:10.2147/ijn.s231479 · Cited by 131
Prabhudesai, S., Wang, N. C., Ahluwalia, V., Huan, X., Bapuraj, J. R., Banovic, N., & Rao, A. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.740353 · Cited by 13
Rimmer, B., Dutton, L., Lewis, J., Burns, R., Gallagher, P., Williams, S., Araujo-Soares, V., Finch, T., & Sharp, L. (2020) · BMJ Open · doi:10.1136/bmjopen-2020-041465 · Cited by 12
Metadata
- Authors
- Forst, D. A., Nahed, B. V., Loeffler, J. S., & Batchelor, T. T.
- Venue
- The Oncologist
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-03-24
- Volume
- 19
- Issue
- 4
- Pages
- 403-413
- ISSN
- 1083-7159 (ISSN-L)
- 1549-490X
- OpenAlex
- W2123046490
- Cited by
- 253
- References
- 5
- FWCI
- 4.65
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Low-Grade Gliomas. https://app.cochat.ai/papers/10.1634/theoncologist.2013-0345
- The paper
- Forst, D. A., Nahed, B. V., Loeffler, J. S., & Batchelor, T. T. (2014). Low-Grade Gliomas. The Oncologist. https://doi.org/10.1634/theoncologist.2013-0345
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
